Standard BioTools (NASDAQ: LAB) has announced its inaugural Proteomics Roundtable Series, a virtual event program focusing on proteomics advancements in healthcare. The first session, scheduled for June 6, 2025, will feature experts discussing findings from the 30-year EPIC cancer study involving 500,000 participants. The series includes future sessions on comparative metrics for proteomic platforms, biobank research applications, and proteomics in drug development. Dr. Stephen Williams will host the first panel featuring experts from Imperial College London and University of Oxford. The events aim to facilitate discussions about technological advancements and real-world applications in proteomics research.
Standard BioTools (NASDAQ: LAB) ha annunciato la sua prima Proteomics Roundtable Series, un programma di eventi virtuali dedicato ai progressi della proteomica nel settore sanitario. La prima sessione, prevista per il 6 giugno 2025, vedr脿 esperti discutere i risultati dello studio EPIC sul cancro, durato 30 anni e che ha coinvolto 500.000 partecipanti. La serie prevede future sessioni su metriche comparative per piattaforme proteomiche, applicazioni nella ricerca sui biobanche e proteomica nello sviluppo di farmaci. Il dottor Stephen Williams condurr脿 il primo panel con esperti dell'Imperial College di Londra e dell'Universit脿 di Oxford. Gli eventi mirano a favorire il confronto sui progressi tecnologici e le applicazioni pratiche nella ricerca proteomica.
Standard BioTools (NASDAQ: LAB) ha anunciado su primera serie de mesas redondas sobre prote贸mica, un programa virtual centrado en los avances de la prote贸mica en el cuidado de la salud. La primera sesi贸n, programada para el 6 de junio de 2025, contar谩 con expertos que discutir谩n los hallazgos del estudio EPIC sobre c谩ncer, de 30 a帽os de duraci贸n y con 500,000 participantes. La serie incluir谩 futuras sesiones sobre m茅tricas comparativas para plataformas prote贸micas, aplicaciones en investigaci贸n de biobancos y prote贸mica en el desarrollo de f谩rmacos. El Dr. Stephen Williams ser谩 el moderador del primer panel con expertos del Imperial College de Londres y la Universidad de Oxford. Los eventos buscan facilitar discusiones sobre avances tecnol贸gicos y aplicaciones pr谩cticas en la investigaci贸n prote贸mica.
Standard BioTools (NASDAQ : LAB) a annonc茅 sa premi猫re s茅rie de tables rondes sur la prot茅omique, un programme d'茅v茅nements virtuels ax茅 sur les avanc茅es en prot茅omique dans le domaine de la sant茅. La premi猫re session, pr茅vue le 6 juin 2025, r茅unira des experts pour discuter des r茅sultats de l'茅tude EPIC sur le cancer, men茅e sur 30 ans et impliquant 500 000 participants. La s茅rie comprendra des sessions futures sur les m茅triques comparatives des plateformes prot茅omiques, les applications en recherche sur les biobanques et la prot茅omique dans le d茅veloppement de m茅dicaments. Le Dr Stephen Williams animera le premier panel avec des experts de l鈥橧mperial College de Londres et de l鈥橴niversit茅 d鈥橭xford. Ces 茅v茅nements visent 脿 favoriser les 茅changes sur les avanc茅es technologiques et les applications concr猫tes en recherche prot茅omique.
Standard BioTools (NASDAQ: LAB) hat seine erste Proteomics Roundtable Series angek眉ndigt, ein virtuelles Veranstaltungsprogramm, das sich auf Fortschritte in der Proteomik im Gesundheitswesen konzentriert. Die erste Sitzung, geplant f眉r den 6. Juni 2025, wird Experten zusammenbringen, die Ergebnisse der 30-j盲hrigen EPIC-Krebsstudie mit 500.000 Teilnehmern diskutieren. Die Serie umfasst zuk眉nftige Sitzungen zu vergleichenden Metriken f眉r proteomische Plattformen, Anwendungen in der Biobankforschung und Proteomik in der Arzneimittelentwicklung. Dr. Stephen Williams wird die erste Podiumsdiskussion mit Experten vom Imperial College London und der Universit盲t Oxford moderieren. Ziel der Veranstaltungen ist es, den Austausch 眉ber technologische Fortschritte und praktische Anwendungen in der Proteomikforschung zu f枚rdern.
Positive
None.
Negative
None.
Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of its inaugural 鈥� a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking research, technological advancements and real-world applications of proteomics shaping the future of healthcare.
The first session will be:
Is More AG真人官方ly More? Evaluating the Case for High-Plex, High-Quality Proteomics Friday, June 6, 2025 鈥� 11:00 am ET
Stephen Williams, MD, PhD, Chief Medical Officer at Standard BioTools will host a panel featuring investigators from the 30-year, 500,000-participant EPIC cancer study. These researchers will explain how they found 鈥渂lack swan鈥� insights into the development of major cancers from proteins previously unmeasurable across massive cohorts.聽Speakers for this session include:
Elio Riboli, MD 鈥� Professor of Cancer Epidemiology, Imperial College London
Marc Gunter, PhD 鈥� Professor and Chair in Cancer Epidemiology and Prevention, Imperial College London
Karl Smith-Byrne, DPhil 鈥� Senior Molecular Epidemiologist, University of Oxford
Register for this event:
Upcoming topics for future Proteomics Roundtable events include the following:
Quantifying Confidence: Comparative Metrics for Proteomic Platforms that Matter
In this session, leading proteomics researchers will dive into differentiators in proteomics. From dispelling cross-reactivity myths to explaining head-to-head data, learn how researchers evaluate technologies for massive-scale studies.
Trusted at Scale: Deployment of Proteomic Technologies in Biobanks
Find out how leading biobank researchers are translating large-scale proteomic data into real-world insights. As biobank investigators work to advance research across diverse populations, platform choice becomes mission-critical and focused on balancing throughput, reproducibility and depth of measurement.
Accelerating Drug Development: Proteomics in Clinical Trials
Top biopharma innovators are using the SomaScan鈩� Assay to accelerate decision making and de-risk drug development, while getting closer to patients. Researchers will discuss how proteomics is delivering the insights they need to find better drugs, faster.
Registration & Participation:
Individuals interested in attending these virtual events can register via the Standard BioTools website at where future updates will also be provided. These sessions will be webcast on the Investor page of the Company鈥檚 website and will be available for replay.
About Standard BioTools Inc.聽
Standard BioTools Inc.聽(Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes.聽Standard BioTools聽works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at聽聽or connect with us on X, Facebook and LinkedIn.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: Patent and License Information:聽. 罢谤补诲别尘补谤办蝉:听. Any other trademarks are the sole property of their respective owners. 漏2025聽Standard BioTools Inc.聽(f.k.a.聽Fluidigm Corporation). All rights reserved.
Media Contact听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听 Emilia Costales听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听听 别尘颈濒颈补.肠辞蝉迟补濒别蝉蔼蝉迟补苍诲补谤诲产颈辞.肠辞尘听听听听听听听听听听听听听听听听
Investor Contact 颈谤蔼蝉迟补苍诲补谤诲产颈辞.肠辞尘听听听听听听听听
FAQ
When is Standard BioTools (LAB) hosting its first Proteomics Roundtable webcast?
Standard BioTools will host its first Proteomics Roundtable webcast on Friday, June 6, 2025, at 11:00 am ET.
Who are the speakers for Standard BioTools' first Proteomics Roundtable session?
The speakers include Dr. Stephen Williams (Chief Medical Officer at Standard BioTools), Dr. Elio Riboli (Professor at Imperial College London), Dr. Marc Gunter (Professor at Imperial College London), and Dr. Karl Smith-Byrne (Senior Molecular Epidemiologist, University of Oxford).
What topics will be covered in Standard BioTools' Proteomics Roundtable series?
The series will cover topics including high-plex proteomics in cancer research, comparative metrics for proteomic platforms, proteomics deployment in biobanks, and proteomics applications in drug development clinical trials.
How can investors access Standard BioTools' Proteomics Roundtable webcasts?
Investors can register through Standard BioTools' website at standardbio.com/2025-proteomics-roundtable. The sessions will be webcast on the company's Investor page and will be available for replay.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
